Guiding diabetes screening and prevention: rationale, recommendations and remaining challenges.
Guiding diabetes screening and prevention: rationale, recommendations and remaining challenges. Expert Rev Endocrinol Metab. 2015 Jul;10(4):381-398 Authors: Aroda VR, Getaneh A Abstract Advances made in diabetes management are not sufficient to reduce morbidity, mortality and cost without making prevention efforts at various levels imperative for substantial impact. Research has demonstrated the efficacy of lifestyle intervention and medications in preventing type 2 diabetes among diverse high-risk groups commonly identified with oral glucose tolerance testing. Efficacy, sustainability and safety data are most comprehensive for lifestyle and metformin, with other medications also demonstrating efficacy and potential in the pharmacoprevention of diabetes. Subsequent implementation studies have demonstrated feasibility of lifestyle intervention programs at health centers, communities, and at local and national government levels. Challenges remain in widespread translation and reaching and engaging at-risk individuals and populations. PMID: 30293496 [PubMed]
Condition: Type2 Diabetes Interventions: Other: Balanced diet high in Slowly Digestible Starch; Other: Balanced diet low in Slowly Digestible Starch Sponsors: Mondelēz International, Inc.; Centre de Recherche en Nutrition Humaine Rhone-Alpe; Biofortis Mérieux NutriSciences Not yet recruiting
Conditions: Diabetic Neuropathy Peripheral; Small Vessel Disease of Diabetes Mellitus; Vasodilation; Vasoconstriction Interventions: Other: " Rest " ; Other: " Exercise " ; Other: " Foot lowering " ; Other: " Hyperthermia " Sponsor: University of Avignon Recruiting
Abstract: Diabetes mellitus is the leading cause of chronic kidney disease (CKD) in the US. An increasing number of glucagon-like peptide-1 receptor agonists are available for diabetes management. Differences between medications in this class, as well as limited data on patients with CKD, underscore the importance of a patient-centered approach to care.
ConclusionsThese findings reveal MLKL as a regulator of insulin sensitivity and suggest necroptotic regulators might be potential therapeutic targets for insulin resistance and T2D.
ConclusionMale FDR of T2DM showed higher level of TC and LDL-C level than those of non FDR. Male FDR also showed higher risk of dyslipidemia.
(BMJ. 2018;361:k2477) Metformin is a commonly used drug for the treatment of type 2 diabetes. It has also been used in women with polycystic ovary syndrome to improve insulin sensitivity. Since 2008 the drug has been recommended for use in pregnancy in the United Kingdom for women with type 2 diabetes or gestational diabetes. However, its use in pregnancy remains controversial as it affects stem cell function and concerns have been raised about potential teratogenic effects. Animal studies and meta-analyses in humans have not provided evidence of increased risk for congenital anomalies. However, one cohort study involving...
First Insulin-Management App Able to Titrate All Types of Insulin Regimens for People with Type 2 Diabetes and Connect To Any Glucose Meter That Shares Data with the Cloud LIVONIA, Mich., Feb. 20, 2019 -- (Healthcare Sales &Marketing Network) -- Hygie... Devices, Endocrinology, FDA Hygieia , insulin-management app, d-Nav Insulin Guidance
Research, published inThe Journal of Clinical Endocrinology& Metabolism, suggests that sunlight exposure may decrease the risk of type-2 diabetes.Healio
DIABETES type 2 risk could be lowered by making some changes to your exercise for diet plans. You could reduce your chances of high blood sugar symptoms and signs by doing this quick exercise after eating a big meal.
ConclusionsBlood glucose fluctuation is an independent risk factor associated with CIMT in T2DM patients, in addition to conventional risk factors, such as smoking, high UA level and 2 h C-peptide. Therefore, more attention should be given to the change of CIMT and the complications.